Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf [Yahoo! Finance]
These Are the Only 3 Stocks That Cathie Wood Bought Last Week [Yahoo! Finance]
Arcturus Therapeutics (ARCT) was upgraded by B. Riley Financial, Inc. to "strong-buy".
Arcturus Therapeutics (ARCT) is now covered by B. Riley Financial, Inc.. They set a "buy" rating and a $22.00 price target on the stock.
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing [Yahoo! Finance]